|
|
Article: Cobalis Reports Phase III Trial Results for PreHistin(TM) in Seasonal Allergic Rhinitis.
- Article from:
- Business Wire
- Article date:
- July 6, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Low Symptom Levels in Overall Patient Population Lead to Inconclusive Outcome
IRVINE, Calif. -- Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today reported preliminary top-line results from two Phase III clinical trials for its drug PreHistin[TM] in patients with moderate to moderately severe seasonal allergic rhinitis, commonly known as hay fever. The trials showed very low symptom levels in both placebo and PreHistin-treated patient groups, thereby leaving no room to demonstrate a meaningful drug effect.
In the randomized, six week, placebo-controlled trials involving a total of 1,551 ...